FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084891107> ?p ?o ?g. }

• W2084891107 endingPage "213" @default.
• W2084891107 startingPage "200" @default.
• W2084891107 abstract "Despite being a pleiotropic cytokine, the therapeutic potential of interferon α2b (IFNα2b) is debatable. Thus, the need for identifying predictive marker(s) for patients who are most likely to benefit from the treatment is pivotal for avoiding the exposure of nonresponsive patients to the toxicity of the treatment. To account for the attenuated efficacy of the drug, we have verified its dendritic cell (DC) maturating ability from monocytes of cervical cancer stage IIIB (CaCx-IIIB) patients. First, we evaluated the status of monocytes from CaCx-IIIB and healthy women by conducting flow cytometric studies of various activation markers and a cytokine analysis by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Immature DCs were then generated from these monocytes and matured with low-dose IFNα2b (1500 units/mL). A functional and phenotypic comparative analysis of these matured DCs was performed by flow cytometric, proliferative, cytotoxic, and enzyme-linked immunosorbent assays. Our study shows that monocytes isolated from CaCx-IIIB are impaired, and in vitro maturation with IFNα2b did not significantly improve the functional repertoire of DCs generated from these monocytes in comparison with healthy controls. This impairment of monocytes might be a plausible reason for the attenuated efficacy of this drug alone in treating CaCx-IIIB patients, and this imbalance of immune parameters associated with the stage of malignancy might be considered an effective marker to design a proper therapeutic regimen. Despite being a pleiotropic cytokine, the therapeutic potential of interferon α2b (IFNα2b) is debatable. Thus, the need for identifying predictive marker(s) for patients who are most likely to benefit from the treatment is pivotal for avoiding the exposure of nonresponsive patients to the toxicity of the treatment. To account for the attenuated efficacy of the drug, we have verified its dendritic cell (DC) maturating ability from monocytes of cervical cancer stage IIIB (CaCx-IIIB) patients. First, we evaluated the status of monocytes from CaCx-IIIB and healthy women by conducting flow cytometric studies of various activation markers and a cytokine analysis by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Immature DCs were then generated from these monocytes and matured with low-dose IFNα2b (1500 units/mL). A functional and phenotypic comparative analysis of these matured DCs was performed by flow cytometric, proliferative, cytotoxic, and enzyme-linked immunosorbent assays. Our study shows that monocytes isolated from CaCx-IIIB are impaired, and in vitro maturation with IFNα2b did not significantly improve the functional repertoire of DCs generated from these monocytes in comparison with healthy controls. This impairment of monocytes might be a plausible reason for the attenuated efficacy of this drug alone in treating CaCx-IIIB patients, and this imbalance of immune parameters associated with the stage of malignancy might be considered an effective marker to design a proper therapeutic regimen." @default.
• W2084891107 created "2016-06-24" @default.
• W2084891107 creator A5005354760 @default.
• W2084891107 creator A5023408129 @default.
• W2084891107 creator A5035167563 @default.
• W2084891107 creator A5053729406 @default.
• W2084891107 creator A5056288375 @default.
• W2084891107 creator A5060474466 @default.
• W2084891107 creator A5063597228 @default.
• W2084891107 creator A5080946365 @default.
• W2084891107 creator A5081385443 @default.
• W2084891107 creator A5082768046 @default.
• W2084891107 creator A5086172980 @default.
• W2084891107 creator A5090920964 @default.
• W2084891107 date "2011-10-01" @default.
• W2084891107 modified "2023-09-27" @default.
• W2084891107 title "Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon α2b (IFNα2b) in cervical cancer" @default.
• W2084891107 cites W1566579330 @default.
• W2084891107 cites W1638465953 @default.
• W2084891107 cites W1666079001 @default.
• W2084891107 cites W1775749144 @default.
• W2084891107 cites W1865859124 @default.
• W2084891107 cites W1973988089 @default.
• W2084891107 cites W1994998729 @default.
• W2084891107 cites W1998593536 @default.
• W2084891107 cites W2010230397 @default.
• W2084891107 cites W2011648441 @default.
• W2084891107 cites W2016199123 @default.
• W2084891107 cites W2021718125 @default.
• W2084891107 cites W2038519121 @default.
• W2084891107 cites W2044389879 @default.
• W2084891107 cites W2048662192 @default.
• W2084891107 cites W2060865004 @default.
• W2084891107 cites W2062479833 @default.
• W2084891107 cites W2063054909 @default.
• W2084891107 cites W2065572086 @default.
• W2084891107 cites W2071422576 @default.
• W2084891107 cites W2075096138 @default.
• W2084891107 cites W2075968543 @default.
• W2084891107 cites W2091114145 @default.
• W2084891107 cites W2098844082 @default.
• W2084891107 cites W2101003487 @default.
• W2084891107 cites W2102875788 @default.
• W2084891107 cites W2116703264 @default.
• W2084891107 cites W2121990521 @default.
• W2084891107 cites W2136443107 @default.
• W2084891107 cites W2136621854 @default.
• W2084891107 cites W2137153097 @default.
• W2084891107 cites W2144697790 @default.
• W2084891107 cites W2151101205 @default.
• W2084891107 cites W2160236174 @default.
• W2084891107 cites W2169083786 @default.
• W2084891107 cites W2327278677 @default.
• W2084891107 cites W2399496617 @default.
• W2084891107 cites W2403402071 @default.
• W2084891107 cites W2405975732 @default.
• W2084891107 cites W2412314779 @default.
• W2084891107 cites W2412971678 @default.
• W2084891107 cites W2417297106 @default.
• W2084891107 cites W1522001928 @default.
• W2084891107 doi "https://doi.org/10.1016/j.trsl.2011.03.003" @default.
• W2084891107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21925117" @default.
• W2084891107 hasPublicationYear "2011" @default.
• W2084891107 type Work @default.
• W2084891107 sameAs 2084891107 @default.
• W2084891107 citedByCount "7" @default.
• W2084891107 countsByYear W20848911072012 @default.
• W2084891107 countsByYear W20848911072013 @default.
• W2084891107 countsByYear W20848911072014 @default.
• W2084891107 countsByYear W20848911072017 @default.
• W2084891107 countsByYear W20848911072018 @default.
• W2084891107 countsByYear W20848911072020 @default.
• W2084891107 crossrefType "journal-article" @default.
• W2084891107 hasAuthorship W2084891107A5005354760 @default.
• W2084891107 hasAuthorship W2084891107A5023408129 @default.
• W2084891107 hasAuthorship W2084891107A5035167563 @default.
• W2084891107 hasAuthorship W2084891107A5053729406 @default.
• W2084891107 hasAuthorship W2084891107A5056288375 @default.
• W2084891107 hasAuthorship W2084891107A5060474466 @default.
• W2084891107 hasAuthorship W2084891107A5063597228 @default.
• W2084891107 hasAuthorship W2084891107A5080946365 @default.
• W2084891107 hasAuthorship W2084891107A5081385443 @default.
• W2084891107 hasAuthorship W2084891107A5082768046 @default.
• W2084891107 hasAuthorship W2084891107A5086172980 @default.
• W2084891107 hasAuthorship W2084891107A5090920964 @default.
• W2084891107 hasConcept C121608353 @default.
• W2084891107 hasConcept C126322002 @default.
• W2084891107 hasConcept C154317977 @default.
• W2084891107 hasConcept C202751555 @default.
• W2084891107 hasConcept C203014093 @default.
• W2084891107 hasConcept C2776178377 @default.
• W2084891107 hasConcept C2777701055 @default.
• W2084891107 hasConcept C2778690821 @default.
• W2084891107 hasConcept C2779399171 @default.
• W2084891107 hasConcept C2780521871 @default.
• W2084891107 hasConcept C2780841837 @default.
• W2084891107 hasConcept C502942594 @default.
• W2084891107 hasConcept C553184892 @default.

• next